Viridian Therapeutics, Inc.VRDNNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 81% recommend buying.

Consensus Rating

Buy

16 analysts·Moderate coverage

81%

Rating Distribution

Strong Buy

00%

Buy

1381%

Hold

319%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see moderate upside — consensus target 28% higher.

Bear Case

$34.00

+2%

Consensus

$42.89

+28%

Bull Case

$50.00

+49%

Price Range16 analysts

Low

Consensus

High

$34.00

$50.00

Current Target

Current Price

$33.46

Upside to Target

$9.43

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-3.53(11 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+257.64%

EPS—

FY2028

Rev+140.63%

EPS—

FY2029

Rev+37.87%

EPS+126.94%

Earnings Surprises

Beat rate:58%(7/12 quarters)

Avg surprise:-1.8%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 28, 2026Evercore ISI

Viridian Therapeutic (VRDN) PT Raised to $45 at Evercore ISI

Target:$45.00

+35.8%from $33.14

Jan 20, 2026Evercore ISI

Viridian Therapeutics price target raised to $44 from $42 at Evercore ISI

Target:$44.00

+34.8%from $32.63

Jan 7, 2026UBS

Viridian Therapeutics initiated with a Buy at UBS

Target:$50.00

+62.2%from $30.82

Dec 3, 2025William Blair

Viridian Therapeutics initiated with an Outperform at William Blair

Target:$47.00

+54.5%from $30.43

Nov 24, 2025Truist Financial

Viridian Therapeutics initiated with a Buy at Truist

Target:$41.00

+35.1%from $30.34

Nov 6, 2025RBC Capital

Viridian Therapeutics price target raised to $45 from $41 at RBC Capital

Target:$45.00

+63.6%from $27.50

Nov 6, 2025Goldman Sachs

Viridian Therapeutics price target raised to $40 from $30 at Goldman Sachs

Target:$40.00

+42.3%from $28.11

Nov 5, 2025Stifel Nicolaus

Viridian Therapeutic (VRDN) PT Raised to $48 at Stifel

Target:$48.00

+98.0%from $24.24

Oct 21, 2025Oppenheimer

Viridian Therapeutics price target raised to $36 from $32 at Oppenheimer

Target:$36.00

+47.0%from $24.48

Oct 21, 2025H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Viridian Therapeutic (VRDN)

Target:$34.00

+41.1%from $24.09

Nov 12, 2024Stifel Nicolaus

Viridian Therapeutic (VRDN) PT Raised to $41 at Stifel

Target:$41.00

+259.3%from $11.41

Sep 13, 2024RBC Capital

Viridian Therapeutics price target raised to $44 from $35 at RBC Capital

Target:$44.00

+325.1%from $10.35

Sep 11, 2024Needham

Viridian Therapeutic (VRDN) PT Raised to $38 at Needham

Target:$38.00

+299.6%from $9.51

Sep 11, 2024B.Riley Financial

Viridian Therapeutic (VRDN) PT Raised to $22 at B.Riley

Target:$22.00

+14.3%from $19.24

Sep 10, 2024Stifel Nicolaus

Viridian Therapeutics price target raised to $40 from $33 at Stifel

Target:$40.00

+360.8%from $8.68

Sep 10, 2024BTIG

Viridian Therapeutic (VRDN) PT Raised to $56 at BTIG

Target:$56.00

+548.1%from $8.64

Aug 14, 2024Goldman Sachs

Goldman Sachs Reiterates Buy Rating on Viridian Therapeutic (VRDN)

Target:$25.00

+76.3%from $14.18

Jun 11, 2024RBC Capital

RBC Capital Reiterates Outperform Rating on Viridian Therapeutic (VRDN)

Target:$35.00

+440.1%from $6.48

Jun 11, 2024BTIG

BTIG Reiterates Buy Rating on Viridian Therapeutic (VRDN)

Target:$46.00

+609.9%from $6.48

Jun 10, 2024Wolfe Research

Viridian Therapeutics initiated with an Outperform at Wolfe Research

Target:$29.00

+374.6%from $6.11

Jun 6, 2024Goldman Sachs

Viridian Therapeutics initiated with a Buy at Goldman Sachs

Target:$23.00

+272.8%from $6.17

May 9, 2024Oppenheimer

Viridian Therapeutic (VRDN) PT Lowered to $31 at Oppenheimer

Target:$31.00

+316.1%from $7.45

May 9, 2024H.C. Wainwright

Viridian Therapeutic (VRDN) PT Lowered to $27 at H.C. Wainwright

Target:$27.00

+262.4%from $7.45

May 9, 2024B.Riley Financial

B.Riley Downgrades Viridian Therapeutic (VRDN) to Neutral

Target:$20.00

+34.2%from $14.90

Jan 9, 2023Leerink Partners

SVB Leerink Maintains Outperform on Viridian Therapeutics, Raises Price Target to $45

Target:$45.00

+63.9%from $27.46

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance